ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

JL19001

A development code. Also written as “JL19001, subcutaneous injection, 1 μg/kg”, “JL19001, subcutaneous injection, 5 μg/kg” and “JL19001, subcutaneous injection,10 μg/kg”.

Its studies are mostly in Lymphoma, Non-Hodgkin · Non-Muscle Invasive Bladder Neoplasms, led by Jecho Biopharmaceuticals.

Furthest: phase 1, since Mar 9, 20262 company-led studies, 2 open or runningNext primary completion: Mar 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jecho Biopharmaceuticals22 open or runningphase 1since Mar 9, 2026Mar 9, 2026Mar 30, 2027phase 1 · NCT07483970

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 9, 2026First study: phase 1 study in High Risk Non-muscle Invasive Bladder CancerFirst studyNCT07483970 · 18 planned · China
  2. May 18, 2026Phase 1 study in NeoplasmsNCT07603479 · 14 planned · China

Ahead

  1. Mar 30, 2027Primary completion: phase 1 study in High Risk Non-muscle Invasive Bladder CancerNCT07483970
  2. May 2030Primary completion: phase 1 study in NeoplasmsNCT07603479

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07603479Neoplasms · China1RecruitingMay 203014
NCT07483970High Risk Non-muscle Invasive Bladder Cancer · China1RecruitingMar 30, 202718

How it is read

Names in the registry

  • “JL19001, subcutaneous injection, 1 μg/kg”, 1 entry
  • “JL19001, subcutaneous injection, 5 μg/kg”, 1 entry
  • “JL19001, subcutaneous injection,10 μg/kg”, 1 entry
  • “JL19001, subcutaneous injection,15 μg/kg”, 1 entry
  • “JL19001, subcutaneous injection,20 μg/kg”, 1 entry

Codes read as this program: JL19001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
JL19001 (Jecho Biopharmaceuticals): development program | ClinicalTrials.gg